Core Insights - The ENSURE II study results have been published in the peer-reviewed journal Nature Medicine, evaluating the efficacy and safety of the siRNA drug elebsiran in combination with PEG-IFNα for chronic hepatitis B treatment [1][2] - The study also explores the potential role of the therapeutic vaccine BRII-179 in enhancing immune response and HBsAg clearance rates in patients [1] Group 1: Study Design and Methodology - The ENSURE study was conducted in two parts: the first part involved participants who had not previously received BRII-179, randomly assigned to either 48 weeks of PEG-IFNα monotherapy or combination therapy with elebsiran [2] - The second part included participants from a prior study who had received elebsiran and BRII-179, categorized based on their anti-HBs peak levels, and subsequently treated with elebsiran and PEG-IFNα [2] Group 2: Research Implications - The lead researcher, Professor Jia Jidong, emphasized that the ENSURE study aims to provide scientific evidence for curative therapies for chronic hepatitis B and address key scientific questions [3] - Encouragingly, the 24-week follow-up data aligns with the results at the end of treatment, supporting the additional clinical benefits of elebsiran and indicating the potential new role of BRII-179 in activating the immune response in chronic hepatitis B patients [3]
腾盛博药-B(02137)：在《自然?医学》发表ENSURE II期研究结果